Glen Eagle Advisors, LLC Vertex Pharmaceuticals Inc Transaction History
Glen Eagle Advisors, LLC
- $546 Billion
- Q2 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 15 shares of VRTX stock, worth $7,282. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15Holding current value
$7,282% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding VRTX
# of Institutions
1,707Shares Held
226MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$13 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$11.2 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.3 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.69 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.15 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $125B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...